150 related articles for article (PubMed ID: 17011205)
1. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
2. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease.
Saydoff JA; Liu LS; Garcia RA; Hu Z; Li D; von Borstel RW
Brain Res; 2003 Dec; 994(1):44-54. PubMed ID: 14642447
[TBL] [Abstract][Full Text] [Related]
3. Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine.
Garcia RA; Liu L; Hu Z; Gonzalez A; von Borstel RW; Saydoff JA
Brain Res; 2005 Dec; 1066(1-2):164-71. PubMed ID: 16330000
[TBL] [Abstract][Full Text] [Related]
4. Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models.
Saydoff JA; Olariu A; Sheng J; Hu Z; Li Q; Garcia R; Pei J; Sun GY; von Borstel R
J Alzheimers Dis; 2013; 36(4):637-57. PubMed ID: 23648515
[TBL] [Abstract][Full Text] [Related]
5. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
6. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
7. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms.
Corey-Bloom J; Aikin AM; Gutierrez AM; Nadhem JS; Howell TL; Thomas EA
Brain Res; 2017 Oct; 1673():102-110. PubMed ID: 28823953
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
[TBL] [Abstract][Full Text] [Related]
13. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
Smith KM; Matson S; Matson WR; Cormier K; Del Signore SJ; Hagerty SW; Stack EC; Ryu H; Ferrante RJ
Biochim Biophys Acta; 2006 Jun; 1762(6):616-26. PubMed ID: 16647250
[TBL] [Abstract][Full Text] [Related]
14. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
15. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
16. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
19. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
[TBL] [Abstract][Full Text] [Related]
20. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.
Ramaswamy S; McBride JL; Han I; Berry-Kravis EM; Zhou L; Herzog CD; Gasmi M; Bartus RT; Kordower JH
Neurobiol Dis; 2009 Apr; 34(1):40-50. PubMed ID: 19150499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
